Hemopoietic reserve in the older cancer patient: Clinical and economic considerations

Cancer Control

Volumn 7, Issue 6, 2000, Pages 539-547

  Balducci, Lodovico ^a   Hardy, Cheryl L ^b   Lyman, Gary H ^c,d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PIRARUBICIN; PREDNIMUSTINE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DRUG COST; DRUG SAFETY; GERIATRIC DISORDER; HUMAN;

EID: 0033646738     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480000700605     Document Type: Article

References (54)

1. Physiology of aging: Relevance to symptom perceptions and treatment tolerance
2. Antineoplastic chemotherapy of the older cancer patient
3. Cancer chemotherapy in the older patient
4. Hemopoiesis and aging
5. Hemopoietic alterations of cancer
6. Decline in the growth potential of spleen-colonizing bone marrow stem cells of long-lived aging mice
7. Hematopoiesis and cytokines. Relevance to cancer and aging
8. Age-related declines in hematopoietic reserve capacity
9. Kinetic evaluation of the pool sizes and proliferative response of neutrophils in bacterially challenged aging mice
10. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers
11. Anemia of aging: A model of erythropoiesis in cancer patients
12. Hematopoiesis and aging III: Anemia and a blunted erythropoietic response to hemorrhage in aged mice
13. Infections in the older cancer patient
14. The aging bone marrow
15. Admission criteria for immunogerontological studies in man: The SENIEUR protocol
16. Interleukin-6 and aging: Blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction
17. Recombinant hemopoietic growth factors: Comparative hemopoietic response in younger and older subjects
18. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group
19. Bone marrow transplant in the older person
20. Chemotherapy of metastatic breast cancer in the elderly: The Piedmont Oncology Association experience
21. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trend in toxicity by using doses based on creatinine clearance
22. Should age be a determinant factor in treating breast cancer patients with combination chemotherapy?
23. Cancer treatment and age: Patient perspectives
24. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center Study
25. Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen. Experience on 350 patients
26. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
27. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity
28. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment and survival. A Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years
29. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
30. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: Feasibility and efficacy of an intensive multidrug regimen
31. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy
32. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age
33. A randomized placebo-controlled study on granulocyte macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
34. Hematopoietic growth factors as adjuncts to the treatment of acute myelogenous leukemia
35. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
36. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients-with-previously untreated acute myelogenous leukemia: A Southwest Oncology Group study (9031)
37. Acute myelogenous leukemia and aging. Clinical interactions
38. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis
39. Once-weekly dosing of epoetin alfa is similar to three-times-weekly dosing in increasing hemoglobin and quality of life
40. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel and cisplatin combination chemotherapy: Results of a randomized comparison
41. Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability
42. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy
43. The association of intraoperative factors with the development of postoperative delirium
44. Report of the panel on clinical guidelines for the management of the older cancer patients
45. Assessment of the older cancer patient
46. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines
47. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy
48. The economics of febrile neutropenia: Implications for the use of colony stimulating factors
49. Colony stimulating factors (CSFS) may reduce complications and death in solid tumor patients (pts) with fever and neutropenia
50. Economic analysis of expensive technologies: The case of erythropoietin
51. Impact of cancer-related fatigue on the lives of patients
52. Management of cancer in the older person: A practical approach
53. Cancer in the frail patient. A coming epidemic
54. The predictive value of body protein for chemotherapy-induced toxicity